Results 161 to 170 of about 82,620 (274)

Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients

open access: yes
Cancer Communications, EarlyView.
Anna Petrackova   +5 more
wiley   +1 more source

A distinctive cutaneous malignant neoplasm expressing the langerhans cell phenotype. Synchronous occurrence with B-chronic lymphocytic leukemia [PDF]

open access: bronze, 1985
Franco Bonetti   +8 more
openalex   +1 more source

Drug delivery pathways to the central nervous system via the brain glymphatic system circumventing the blood‐brain barrier

open access: yesExploration, EarlyView.
The discovery of the glymphatic system has opened up a pathway for drug delivery to the brain by circumventing the blood‐brain barrier, which can effectively improve drug utilization. The methods of drug delivery through the glymphatic system include intrathecal injection, intranasal injection, and delivery through the meningeal lymphatic vessels.
Xiang Wang   +7 more
wiley   +1 more source

Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. [PDF]

open access: bronze, 1989
Zev Sthoeger   +9 more
openalex   +1 more source

Synthetic Biology‐Based Engineering Cells for Drug Delivery

open access: yesExploration, EarlyView.
Synthetic biology‐based therapeutic cells for drug delivery: Engineered cells effectively transport and release drugs through their intelligence and controllability, such as feedback pathways and external stimuli (e.g., light and ultrasound). The integration of nanotechnology, including nanoparticles, biofilms, and artificial cells, enhances ...
Wenzhe Yi   +4 more
wiley   +1 more source

T-suppressor cell chronic lymphocytic leukemia. Phenotypic characterization by monoclonal antibodies [PDF]

open access: bronze, 1984
Kamal Bakri   +7 more
openalex   +1 more source

Greek Consensus on Chronic Lymphocytic Leukemia (CLL) Treatment. [PDF]

open access: yesMediterr J Hematol Infect Dis
Sachanas S   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy